Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics is making strides in the healthcare market with the commercial launch and regulatory clearance of its flagship diagnostic products, FebriDx and ViraDx, in the United States. The company’s partnership with Hologic has strengthened its financial position and highlights its commitment to advancing women’s health diagnostics. A recent capital raise of A$10.0 million will support further expansion and product development, positioning Lumos for future growth and shareholder value.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.